CA2307320A1 - 148 proteines humaines secretees - Google Patents
148 proteines humaines secretees Download PDFInfo
- Publication number
- CA2307320A1 CA2307320A1 CA002307320A CA2307320A CA2307320A1 CA 2307320 A1 CA2307320 A1 CA 2307320A1 CA 002307320 A CA002307320 A CA 002307320A CA 2307320 A CA2307320 A CA 2307320A CA 2307320 A1 CA2307320 A1 CA 2307320A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- tissues
- polypeptides
- polynucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 714
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 252
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 358
- 102000040430 polynucleotide Human genes 0.000 claims description 358
- 239000002157 polynucleotide Substances 0.000 claims description 357
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 331
- 229920001184 polypeptide Polymers 0.000 claims description 329
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 329
- 230000014509 gene expression Effects 0.000 claims description 211
- 239000000047 product Substances 0.000 claims description 131
- 125000003729 nucleotide group Chemical group 0.000 claims description 124
- 239000002773 nucleotide Substances 0.000 claims description 67
- 239000012472 biological sample Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 239000002299 complementary DNA Substances 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000004166 bioassay Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 610
- 210000004027 cell Anatomy 0.000 description 391
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 331
- 208000035475 disorder Diseases 0.000 description 258
- 235000018102 proteins Nutrition 0.000 description 241
- 239000000523 sample Substances 0.000 description 114
- 210000001124 body fluid Anatomy 0.000 description 112
- 238000011282 treatment Methods 0.000 description 102
- 238000003745 diagnosis Methods 0.000 description 100
- 201000010099 disease Diseases 0.000 description 73
- 210000002751 lymph Anatomy 0.000 description 62
- 239000003153 chemical reaction reagent Substances 0.000 description 61
- 230000004069 differentiation Effects 0.000 description 61
- 206010028980 Neoplasm Diseases 0.000 description 59
- 238000009826 distribution Methods 0.000 description 59
- 208000026278 immune system disease Diseases 0.000 description 59
- 230000035755 proliferation Effects 0.000 description 59
- 239000012530 fluid Substances 0.000 description 58
- 238000009169 immunotherapy Methods 0.000 description 58
- 230000001900 immune effect Effects 0.000 description 57
- 210000002381 plasma Anatomy 0.000 description 57
- 210000002966 serum Anatomy 0.000 description 57
- 210000001179 synovial fluid Anatomy 0.000 description 57
- 210000002700 urine Anatomy 0.000 description 57
- 239000000439 tumor marker Substances 0.000 description 54
- 230000001537 neural effect Effects 0.000 description 43
- 238000001514 detection method Methods 0.000 description 37
- 206010039073 rheumatoid arthritis Diseases 0.000 description 36
- 210000000130 stem cell Anatomy 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 32
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 30
- 230000004913 activation Effects 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 28
- 210000000987 immune system Anatomy 0.000 description 27
- 230000008569 process Effects 0.000 description 27
- 206010003246 arthritis Diseases 0.000 description 26
- 208000032839 leukemia Diseases 0.000 description 26
- 230000019491 signal transduction Effects 0.000 description 26
- 208000016192 Demyelinating disease Diseases 0.000 description 23
- 208000004235 neutropenia Diseases 0.000 description 23
- 210000003169 central nervous system Anatomy 0.000 description 22
- 210000000440 neutrophil Anatomy 0.000 description 22
- 208000030507 AIDS Diseases 0.000 description 21
- 208000006673 asthma Diseases 0.000 description 21
- 210000000481 breast Anatomy 0.000 description 20
- 208000002874 Acne Vulgaris Diseases 0.000 description 19
- 208000029462 Immunodeficiency disease Diseases 0.000 description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 19
- 201000004681 Psoriasis Diseases 0.000 description 19
- 206010040047 Sepsis Diseases 0.000 description 19
- 206010000496 acne Diseases 0.000 description 19
- 230000030741 antigen processing and presentation Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000024833 regulation of cytokine production Effects 0.000 description 19
- 230000028993 immune response Effects 0.000 description 18
- 208000015122 neurodegenerative disease Diseases 0.000 description 17
- 210000000056 organ Anatomy 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 206010039710 Scleroderma Diseases 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000024245 cell differentiation Effects 0.000 description 16
- 210000000349 chromosome Anatomy 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 16
- 208000024827 Alzheimer disease Diseases 0.000 description 15
- 208000012239 Developmental disease Diseases 0.000 description 15
- 206010020751 Hypersensitivity Diseases 0.000 description 15
- 230000033228 biological regulation Effects 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000003394 haemopoietic effect Effects 0.000 description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 15
- 206010012305 Demyelination Diseases 0.000 description 14
- 208000009329 Graft vs Host Disease Diseases 0.000 description 14
- 206010018691 Granuloma Diseases 0.000 description 14
- 206010029379 Neutrophilia Diseases 0.000 description 14
- 208000021386 Sjogren Syndrome Diseases 0.000 description 14
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 14
- 230000005784 autoimmunity Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 208000007475 hemolytic anemia Diseases 0.000 description 14
- 230000009610 hypersensitivity Effects 0.000 description 14
- 230000036737 immune function Effects 0.000 description 14
- 230000008105 immune reaction Effects 0.000 description 14
- 208000000509 infertility Diseases 0.000 description 14
- 230000036512 infertility Effects 0.000 description 14
- 231100000535 infertility Toxicity 0.000 description 14
- 230000002062 proliferating effect Effects 0.000 description 14
- 230000001850 reproductive effect Effects 0.000 description 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 14
- 208000037816 tissue injury Diseases 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 230000001363 autoimmune Effects 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 201000000980 schizophrenia Diseases 0.000 description 13
- 206010000117 Abnormal behaviour Diseases 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 230000019771 cognition Effects 0.000 description 12
- 230000013016 learning Effects 0.000 description 12
- 230000004770 neurodegeneration Effects 0.000 description 12
- 230000006576 neuronal survival Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 208000020431 spinal cord injury Diseases 0.000 description 12
- 210000000225 synapse Anatomy 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 230000008733 trauma Effects 0.000 description 12
- 206010012289 Dementia Diseases 0.000 description 11
- 206010026749 Mania Diseases 0.000 description 11
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 11
- 206010033864 Paranoia Diseases 0.000 description 11
- 208000027099 Paranoid disease Diseases 0.000 description 11
- 208000018737 Parkinson disease Diseases 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 208000019906 panic disease Diseases 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 206010010356 Congenital anomaly Diseases 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000009826 neoplastic cell growth Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 206010002329 Aneurysm Diseases 0.000 description 9
- 206010003805 Autism Diseases 0.000 description 9
- 208000020706 Autistic disease Diseases 0.000 description 9
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 9
- 208000023105 Huntington disease Diseases 0.000 description 9
- 201000009906 Meningitis Diseases 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 208000028017 Psychotic disease Diseases 0.000 description 9
- 208000000323 Tourette Syndrome Diseases 0.000 description 9
- 208000016620 Tourette disease Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 206010014599 encephalitis Diseases 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000013632 homeostatic process Effects 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 201000003723 learning disability Diseases 0.000 description 9
- 230000036244 malformation Effects 0.000 description 9
- 230000004031 neuronal differentiation Effects 0.000 description 9
- 208000027232 peripheral nervous system disease Diseases 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 230000007958 sleep Effects 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 230000005062 synaptic transmission Effects 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 206010058571 Spinal cord infarction Diseases 0.000 description 8
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000000748 cardiovascular system Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000000066 myeloid cell Anatomy 0.000 description 8
- 210000001258 synovial membrane Anatomy 0.000 description 8
- 210000000133 brain stem Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000011275 oncology therapy Methods 0.000 description 7
- 210000003463 organelle Anatomy 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 208000017701 Endocrine disease Diseases 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002741 palatine tonsil Anatomy 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 208000003669 immune deficiency disease Diseases 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000007261 regionalization Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000018706 hematopoietic system disease Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000004994 reproductive system Anatomy 0.000 description 4
- 208000017443 reproductive system disease Diseases 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000026872 Addison Disease Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 description 3
- 206010021067 Hypopituitarism Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108010067035 Pancrelipase Proteins 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000004404 adrenal cortex Anatomy 0.000 description 3
- 208000017504 atelosteogenesis type II Diseases 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 208000017568 chondrodysplasia Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000000849 parathyroid Effects 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 208000029076 Synovial disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102100025982 BMP/retinoic acid-inducible neural-specific protein 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100392772 Caenorhabditis elegans gln-2 gene Proteins 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016955 Erythrocyte Anion Exchange Protein 1 Human genes 0.000 description 1
- 108010014384 Erythrocyte Anion Exchange Protein 1 Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100272736 Homo sapiens BRINP1 gene Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 1
- 101100386050 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-14 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 101000621749 Penicillium citrinum Peroxiredoxin Pen c 3 Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 108010087132 Sodium-Bicarbonate Symporters Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 101150089730 gly-10 gene Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000031844 regulation of cellular pH Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
Abstract
L'invention concerne de nouvelles protéines humaines sécrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. Elle concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison servant à produire des protéines humaines sécrétées. Elle concerne, de plus, des procédés diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des maladies relatives à ces nouvelles protéines humains sécrétées.
Applications Claiming Priority (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6309197P | 1997-10-24 | 1997-10-24 | |
| US6311097P | 1997-10-24 | 1997-10-24 | |
| US6308897P | 1997-10-24 | 1997-10-24 | |
| US6338797P | 1997-10-24 | 1997-10-24 | |
| US6309297P | 1997-10-24 | 1997-10-24 | |
| US6310197P | 1997-10-24 | 1997-10-24 | |
| US6278497P | 1997-10-24 | 1997-10-24 | |
| US6314897P | 1997-10-24 | 1997-10-24 | |
| US6309797P | 1997-10-24 | 1997-10-24 | |
| US6308997P | 1997-10-24 | 1997-10-24 | |
| US6311197P | 1997-10-24 | 1997-10-24 | |
| US6309097P | 1997-10-24 | 1997-10-24 | |
| US6309897P | 1997-10-24 | 1997-10-24 | |
| US6310997P | 1997-10-24 | 1997-10-24 | |
| US6309997P | 1997-10-24 | 1997-10-24 | |
| US6310097P | 1997-10-24 | 1997-10-24 | |
| US6338697P | 1997-10-24 | 1997-10-24 | |
| US60/063,088 | 1997-10-24 | ||
| US60/063,110 | 1997-10-24 | ||
| US60/063,109 | 1997-10-24 | ||
| US60/063,386 | 1997-10-24 | ||
| US60/063,148 | 1997-10-24 | ||
| US60/063,101 | 1997-10-24 | ||
| US60/063,090 | 1997-10-24 | ||
| US60/062,784 | 1997-10-24 | ||
| US60/063,091 | 1997-10-24 | ||
| US60/063,111 | 1997-10-24 | ||
| US60/063,100 | 1997-10-24 | ||
| US60/063,092 | 1997-10-24 | ||
| US60/063,098 | 1997-10-24 | ||
| US60/063,387 | 1997-10-24 | ||
| US60/063,097 | 1997-10-24 | ||
| US60/063,089 | 1997-10-24 | ||
| US60/063,099 | 1998-07-16 | ||
| PCT/US1998/022376 WO1999022243A1 (fr) | 1997-10-24 | 1998-10-23 | 148 proteines humaines secretees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2307320A1 true CA2307320A1 (fr) | 1999-05-06 |
Family
ID=27586006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002307320A Abandoned CA2307320A1 (fr) | 1997-10-24 | 1998-10-23 | 148 proteines humaines secretees |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1042674A4 (fr) |
| JP (1) | JP2003521865A (fr) |
| AU (1) | AU1273499A (fr) |
| CA (1) | CA2307320A1 (fr) |
| WO (1) | WO1999022243A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1165766A2 (fr) * | 1999-03-05 | 2002-01-02 | Incyte Pharmaceuticals, Inc. | Proteines de secretion humaines |
| US6331413B1 (en) | 1999-03-17 | 2001-12-18 | Zymogenetics, Inc. | Secreted salivary ZSIG63 Polypeptide |
| WO2000071581A1 (fr) * | 1999-05-20 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Nouveau polypeptide |
| FR2796652B1 (fr) * | 1999-07-20 | 2003-03-21 | Inst Nat Sante Rech Med | Acides nucleiques codant pour des peptides possedant l'activite biologique de la sorbine |
| EP1233975A4 (fr) * | 1999-11-05 | 2004-07-07 | Human Genome Sciences Inc | 29 proteines humaines secretees |
| WO2001036685A2 (fr) * | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Expression differentielle de genes dans le cancer |
| US20020086387A1 (en) * | 2000-04-13 | 2002-07-04 | Rachel Meyers | 23155 novel protein human 5-alpha reductases and uses therefor |
| EP1322657A4 (fr) * | 2000-09-12 | 2004-12-29 | Human Genome Sciences Inc | Proteines secretees humaines 22 |
| WO2004039952A2 (fr) * | 2002-10-25 | 2004-05-13 | Five Prime Therapeutics, Inc. | Procedes d'utilisation de polypeptides humains codes par des polynucleotides |
| TW201100090A (en) * | 2009-04-01 | 2011-01-01 | Oncotherapy Science Inc | C6orf167 peptides and vaccines containing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597709A (en) * | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
| EP0796325A4 (fr) * | 1994-12-09 | 1999-11-03 | Human Genome Sciences Inc | Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide |
| KR19990022283A (ko) * | 1995-06-05 | 1999-03-25 | 벤슨 로버트 에이치. | 인체 케모킨 베타-11 및 인체 케모킨 알파-1 |
-
1998
- 1998-10-23 CA CA002307320A patent/CA2307320A1/fr not_active Abandoned
- 1998-10-23 AU AU12734/99A patent/AU1273499A/en not_active Abandoned
- 1998-10-23 EP EP98956146A patent/EP1042674A4/fr not_active Withdrawn
- 1998-10-23 WO PCT/US1998/022376 patent/WO1999022243A1/fr not_active Ceased
- 1998-10-23 JP JP2000518285A patent/JP2003521865A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU1273499A (en) | 1999-05-17 |
| WO1999022243A1 (fr) | 1999-05-06 |
| JP2003521865A (ja) | 2003-07-22 |
| EP1042674A1 (fr) | 2000-10-11 |
| EP1042674A4 (fr) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2339301A1 (fr) | Acides nucleiques et polypeptides relatifs au hdpbo81 | |
| CA2283299A1 (fr) | 186 nouvelles proteines secretees | |
| CA2331154A1 (fr) | Polypeptides presentant une sequence distincte comprenant une sous-unite de facteur de croissance insulinomimetique labile en milieu acide | |
| US20030027132A1 (en) | Secreted Protein HODAZ50 | |
| KR102024186B1 (ko) | 톨-유사 수용체(tlr) 억제를 위한 펩타이드 및 이를 포함하는 약학적 조성물 | |
| US20030204071A1 (en) | 109 human secreted proteins | |
| CA2291260A1 (fr) | 207 proteines secretees par l'etre humain | |
| JP2002533058A (ja) | ９７個のヒト分泌タンパク質 | |
| US6531447B1 (en) | Secreted protein HEMCM42 | |
| CA2319129A1 (fr) | 67 proteines humaines secretees | |
| CA2307320A1 (fr) | 148 proteines humaines secretees | |
| CA2308768A1 (fr) | 125 proteines secretees humaines | |
| KR20030032940A (ko) | 신규 화합물 | |
| CA2323761A1 (fr) | 95 proteines humaines secretees | |
| CA2372926A1 (fr) | 143 proteines humaines secretees | |
| JP2002520050A (ja) | ７１個のヒト分泌タンパク質 | |
| JP2002500035A (ja) | ３６個のヒト分泌タンパク質 | |
| US20020164669A1 (en) | Secreted protein HRGDF73 | |
| CN100549175C (zh) | 一种具有抑癌作用的重组蛋白及其编码基因与应用 | |
| CA2322728A1 (fr) | 31 proteines humaines secretees | |
| JP2001517943A (ja) | ヒト膵炎関連タンパク質、ｐａｐ−２ | |
| KR20200084569A (ko) | Tlr4 신호전달 경로를 억제하는 펩타이드 및 그 용도 | |
| KR102236773B1 (ko) | Tlr4 길항 펩타이드 | |
| US20030144492A1 (en) | 101 human secreted proteins | |
| KR20010043090A (ko) | 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |